Advertisement

Topics

Lipocine Resubmits NDA For Its Oral Testosterone Product Candidate, LPCN 1021, For Treatment Of Hypogonadism

20:00 EDT 8 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Lipocine Resubmits NDA For Its Oral Testosterone Product Candidate, LPCN 1021, For Treatment Of Hypogonadism

NEXT ARTICLE

More From BioPortfolio on "Lipocine Resubmits NDA For Its Oral Testosterone Product Candidate, LPCN 1021, For Treatment Of Hypogonadism"

Quick Search
Advertisement